Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks.
adrenal glands
adrenocortical adenoma
aldosterone
hyperaldosteronism
mutation
Journal
Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
12
2
2019
medline:
16
11
2019
entrez:
12
2
2019
Statut:
ppublish
Résumé
Somatic mutations have been identified in aldosterone-producing adenomas (APAs) in genes that include KCNJ5, ATP1A1, ATP2B3, and CACNA1D. Based on independent studies, there appears to be racial differences in the prevalence of somatic KCNJ5 mutations, particularly between East Asians and Europeans. Despite the high cardiovascular disease mortality of blacks, there have been no studies focusing on somatic mutations in APAs in this population. In the present study, we investigated genetic characteristics of APAs in blacks using a CYP11B2 (aldosterone synthase) immunohistochemistry-guided next-generation sequencing approach. The adrenal glands with adrenocortical adenomas from 79 black patients with primary aldosteronism were studied. Seventy-three tumors from 69 adrenal glands were confirmed to be APAs by CYP11B2 immunohistochemistry. Sixty-five of 73 APAs (89%) had somatic mutations in aldosterone-driver genes. Somatic CACNA1D mutations were the most prevalent genetic alteration (42%), followed by KCNJ5 (34%), ATP1A1 (8%), and ATP2B3 mutations (4%). CACNA1D mutations were more often observed in APAs from males than those from females (55% versus 29%, P=0.033), whereas KCNJ5 mutations were more prevalent in APAs from females compared with those from males (57% versus 13%, P<0.001). No somatic mutations in aldosterone-driver genes were identified in tumors without CYP11B2 expression. In conclusion, 89% of APAs in blacks harbor aldosterone-driving mutations, and unlike Europeans and East Asians, the most frequently mutated aldosterone-driver gene was CACNA1D. Determination of racial differences in the prevalence of aldosterone-driver gene mutations may facilitate the development of personalized medicines for patients with primary aldosteronism.
Identifiants
pubmed: 30739536
doi: 10.1161/HYPERTENSIONAHA.118.12070
pmc: PMC6416065
mid: NIHMS1518903
doi:
Substances chimiques
DNA, Neoplasm
0
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
885-892Subventions
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL027255
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK096994
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115392
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130106
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM115428
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106618
Pays : United States
Références
Science. 2014 May 23;344(6186):917-20
pubmed: 24855271
Sci Rep. 2016 Jan 27;6:19546
pubmed: 26815163
Medicine (Baltimore). 2015 Apr;94(16):e708
pubmed: 25906099
Circulation. 2017 Nov 21;136(21):e393-e423
pubmed: 29061565
Cancer Res. 2005 Sep 1;65(17):7622-7
pubmed: 16140927
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Clin Endocrinol (Oxf). 2015 Dec;83(6):779-89
pubmed: 26252618
Hypertension. 2012 Mar;59(3):592-8
pubmed: 22275527
J Clin Endocrinol Metab. 2016 Mar;101(3):999-1007
pubmed: 26765578
Eur J Endocrinol. 2015 Oct;173(4):465-77
pubmed: 26194502
J Clin Endocrinol Metab. 2012 May;97(5):E819-29
pubmed: 22442279
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4591-9
pubmed: 26240369
J Clin Endocrinol Metab. 2016 Aug;101(8):3010-7
pubmed: 27270477
J Clin Endocrinol Metab. 2012 Apr;97(4):1311-9
pubmed: 22278422
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699
pubmed: 28576687
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Nat Genet. 2018 Mar;50(3):349-354
pubmed: 29403011
Science. 2011 Feb 11;331(6018):768-72
pubmed: 21311022
Pediatr Nephrol. 2013 Apr;28(4):655-60
pubmed: 23179199
Hypertension. 2014 Jun;63(6):1212-8
pubmed: 24711519
J Clin Endocrinol Metab. 2014 Sep;99(9):E1765-73
pubmed: 25057880
Nat Genet. 2013 Sep;45(9):1050-4
pubmed: 23913001
Elife. 2015 Apr 24;4:e06315
pubmed: 25907736
Hypertension. 2015 Mar;65(3):622-8
pubmed: 25624344
Nat Genet. 2013 Sep;45(9):1055-60
pubmed: 23913004
J Clin Endocrinol Metab. 2014 Jul;99(7):E1341-51
pubmed: 24758183
Sci Rep. 2016 Apr 21;6:24697
pubmed: 27098837
Endocrinology. 2015 Dec;156(12):4582-91
pubmed: 26418325
Hypertension. 2018 Jun;71(6):e13-e115
pubmed: 29133356
Hypertension. 2018 Jul;72(1):247-252
pubmed: 29785962
N Engl J Med. 2014 Mar 13;370(11):1019-28
pubmed: 24571724
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3869-3876
pubmed: 30085035
J Clin Endocrinol Metab. 2010 May;95(5):2296-305
pubmed: 20200334
J Atheroscler Thromb. 2015;22(2):191-200
pubmed: 25253161
J Endocr Soc. 2017 May 12;1(7):787-799
pubmed: 29264530
Nat Genet. 2018 Mar;50(3):355-361
pubmed: 29403012
Nat Genet. 2013 Apr;45(4):440-4, 444e1-2
pubmed: 23416519
Hypertension. 2015 Mar;65(3):507-9
pubmed: 25624337
Endocr J. 2016;63(2):199-204
pubmed: 26743443
Sci Rep. 2017 Jan 19;7:39121
pubmed: 28102204
Endocr Relat Cancer. 2015 Oct;22(5):735-44
pubmed: 26285814
Eur J Endocrinol. 2016 Aug;175(2):K1-6
pubmed: 27165862
Hypertension. 2018 Oct;72(4):874-880
pubmed: 30354720
Hypertension. 2014 Aug;64(2):354-61
pubmed: 24866132